Lexicon Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Lexicon Pharmaceuticals de 18.6% y 57.1% por año respectivamente. Se prevé que el BPA crezca en un 28.6% al año. Se espera que la rentabilidad financiera sea de -89.4% en 3 años.

Información clave

18.6%

Tasa de crecimiento de los beneficios

28.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.5%
Tasa de crecimiento de los ingresos	57.1%
Rentabilidad financiera futura	-89.4%
Cobertura de analistas	Good
Última actualización	22 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes

Oct 16

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Aug 08

Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success

Aug 03

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Aug 08

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:LXRX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	49	-154	N/A	N/A	6
12/31/2025	22	-158	N/A	N/A	6
12/31/2024	12	-211	N/A	N/A	6
9/30/2024	5	-216	-208	-208	N/A
6/30/2024	4	-202	-196	-196	N/A
3/31/2024	2	-194	-186	-185	N/A
12/31/2023	1	-177	-162	-162	N/A
9/30/2023	1	-158	-135	-133	N/A
6/30/2023	0	-131	-112	-111	N/A
3/31/2023	0	-110	-99	-97	N/A
12/31/2022	0	-102	-90	-89	N/A
9/30/2022	0	-97	-90	-90	N/A
6/30/2022	0	-97	-88	-88	N/A
3/31/2022	0	-90	-87	-85	N/A
12/31/2021	0	-88	-88	-87	N/A
9/30/2021	0	-68	-100	-98	N/A
6/30/2021	7	38	38	-122	N/A
3/31/2021	16	-13	14	-146	N/A
12/31/2020	24	-59	17	-143	N/A
9/30/2020	33	-104	27	-133	N/A
6/30/2020	320	39	98	98	N/A
3/31/2020	321	85	117	117	N/A
12/31/2019	322	130	114	114	N/A
9/30/2019	330	164	111	111	N/A
6/30/2019	43	-89	-102	-102	N/A
3/31/2019	47	-101	-128	-127	N/A
12/31/2018	63	-121	-149	-149	N/A
9/30/2018	81	-126	-155	-155	N/A
6/30/2018	101	-129	N/A	-167	N/A
3/31/2018	99	-130	N/A	-147	N/A
12/31/2017	92	-123	N/A	-185	N/A
9/30/2017	80	-133	N/A	-200	N/A
6/30/2017	81	-138	N/A	-202	N/A
3/31/2017	89	-141	N/A	-217	N/A
12/31/2016	79	-131	N/A	-176	N/A
9/30/2016	188	-22	N/A	139	N/A
6/30/2016	160	-22	N/A	149	N/A
3/31/2016	141	-11	N/A	165	N/A
12/31/2015	130	-5	N/A	185	N/A
9/30/2015	24	-94	N/A	-86	N/A
6/30/2015	24	-100	N/A	-81	N/A
3/31/2015	24	-98	N/A	-69	N/A
12/31/2014	23	-100	N/A	-76	N/A
9/30/2014	3	-115	N/A	-93	N/A
6/30/2014	3	-106	N/A	-96	N/A
3/31/2014	2	-109	N/A	-97	N/A
12/31/2013	2	-104	N/A	-91	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que LXRX siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que LXRX siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que LXRX siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (57.1% al año) de LXRX crezcan más rápidamente que los del mercado US (8.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (57.1% al año) de LXRX crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: LXRX se prevé que no sea rentable en 3 años.

Lexicon Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 13% to US$4.68

Consensus revenue estimates decrease by 24%

Price target increased by 16% to US$6.25

Price target decreased by 16% to US$5.40

Consensus revenue estimates increase by 33%

Consensus revenue estimates decrease by 41%

Recent updates

Lexicon Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Price target decreased by 13% to US$4.68

Lexicon Pharmaceuticals, Inc. Announces Board Changes

Consensus revenue estimates decrease by 24%

New major risk - Financial position

Price target increased by 16% to US$6.25

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Lexicon Pharmaceuticals, Inc. Publishes Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People with Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Price target decreased by 16% to US$5.40

Lexicon Pharmaceuticals, Inc. Announces Outcome of FDA Advisory Committee for Zynquista (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

Consensus revenue estimates increase by 33%

Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes

Lexicon Pharmaceuticals, Inc. to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

Lexicon Pharmaceuticals, Inc. Appoints Kristen L. Alexander as Its Principal Financial Officer

Lexicon Pharmaceuticals, Inc. Announces Post-Hoc Analysis of Phase 3 Data from the SCORED Clinical Trial

Consensus revenue estimates decrease by 41%

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Lexicon Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Lexicon Pharmaceuticals, Inc. Receives PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission

Lexicon Pharmaceuticals, Inc. Publishes New Data Highlights Potential Cost-Savings of INPEFA®? (sotagliflozin) for Heart Failure

High number of new directors

Lexicon Pharmaceuticals, Inc. Announces Appointment of Mike Exton, Ph.D. as Chief Executive Officer

Lexicon Pharmaceuticals, Inc. Announces CEO Changes

Lexicon Pharmaceuticals, Inc. Announces That Data From it's RELIEF-DPN 1 Phase 2 Study of LX9211 Published in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

Price target increased by 13% to US$6.20

Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much

New major risk - Shareholder dilution

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Lexicon Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024

Lexicon Pharmaceuticals, Inc. Announces Resignation of Lonnel Coats as Chief Executive Officer, Effective from July 7, 2024

Lexicon Pharmaceuticals, Inc., Annual General Meeting, May 10, 2024

Consensus revenue estimates decrease by 44%, EPS upgraded

Lexicon Pharmaceuticals, Inc. announced that it has received $249.99995 million in funding from Braidwell LP, Great Point Partners, LLC, Artal International Management Sa, Artal International SCA, Artal Group S.A.

New major risk - Share price stability

Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis of Intandem3 Study Demonstrates Improvements in Glycemic Control with Sotagliflozin Treatment in Patients with Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Lexicon Pharmaceuticals, Inc. announced that it expects to receive $249.99995 million in funding from Braidwell LP, Great Point Partners, LLC and other investors.

CEO & Director exercised options and sold US$161k worth of stock

Consensus revenue estimates fall by 54%

Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do

Lexicon Pharmaceuticals, Inc. Provides Business and Pipeline Update At 42nd Annual J.P. Morgan Healthcare Conference

Consensus revenue estimates decrease by 12%

Price target decreased by 7.2% to US$5.15

Lexicon Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain

Independent Director recently bought US$202k worth of stock

Consensus revenue estimates decrease by 31%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 30% to US$7.50

Lexicon Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Lexicon Pharmaceuticals, Inc. Appoints Lisa DeFrancesco as Head of Investor Relations and Corporate Strategy, Effective November 13, 2023

Lexicon Pharmaceuticals, Inc. Announces Data from Two Studies Demonstrating Positive Financial Impact of Inpefa (Sotagliflozin) to Be Presented At the Academy of Managed Care Pharmacy Nexus 2023 National Meeting

Independent Chairman of the Board recently bought US$1.1m worth of stock

Lexicon Pharmaceuticals, Inc. Announces the Retirement of Alan S. Nies from Board of Directors, Effective October 26, 2023

New minor risk - Share price stability

Lexicon Pharmaceuticals, Inc. Receives Preferred Formulary Status with Express Scripts for Medicare Patients

Lexicon Pharmaceuticals, Inc. to Present Study Results Relating to Sotagliflozin and Lx9211 At the 59Th Annual Meeting of the European Association for the Study of Diabetes

Consensus EPS estimates fall by 18%

Lexicon Pharmaceuticals, Inc. Announces Published Analysis of Sotagliflozin Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Lexicon Pharmaceuticals, Inc. Elects Diane E. Sullivan to Its Board of Directors

Lexicon Pharmaceuticals, Inc. Announces Resignation of Frank P. Palantoni from Board of Directors, Effective July 27, 2023

CEO & Director recently bought US$92k worth of stock

Lexicon Pharmaceuticals, Inc. Presents Study Results Relating to LX9211 and INPEFA (Sotagliflozin) At the American Diabetes Association’s 83rd Scientific Sessions

Lexicon Pharmaceuticals, Inc. Announces FDA Approval of INPEFA (sotagliflozin) for Treatment of Heart Failure